CMS finalizes plan to boost wage index for rural hospitals

Classic rural farm scene with a weathered red barn, silos, golden crops and a blue sky
CMS released a final rule that increases payments to rural hospitals under Medicare. (Getty/James Pintar)

The Trump administration released a final rule on Friday that boosts Medicare payments to rural hospitals in a bid to address major inequalities.

The Centers for Medicare & Medicaid Services released final rules on Friday for the Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment system for fiscal year 2020. The rules included an increase to the wage index for certain low-wage hospitals such as those in rural areas.

"The changes we’re finalizing in today’s rule are long overdue and improve the way Medicare pays hospitals, which will help many rural hospitals maintain their healthcare labor force," CMS Administrator Seema Verma said in a statement on Friday.

Innovation Awards

Submit your nominations for the FierceHealthcare Innovation Awards

The FierceHealthcare Innovation Awards showcases outstanding innovation that is driving improvements and transforming the industry. Our expert panel of judges will determine which companies demonstrate innovative solutions that have the greatest potential to save money, engage patients, or revolutionize the industry. Deadline for submissions is this Friday, October 18th.

The changes will improve the accuracy of Medicare payments to low-wage hospitals that earn below the 25th percentile of the index.

The policy will be effective for at least four years starting in federal fiscal 2020 on Oct. 1.

Verma told reporters that the boost to the wage index will be budget neutral by "adjusting payments across all hospitals for at least four years."

"With all of those changes together, even high-wage states will see an overall increase in their payments compared to last year," she said on Friday.

CMS also increased the add-on payment to hospitals for treating patients with new technology from 50% to 65% starting on Oct. 1. 

The increase would affect new treatments that include chimeric antigen-receptor T-cell therapy, an expensive immunotherapy that CMS is considering covering.

Suggested Articles

As drugmakers face billions in legal settlements and judgments, we must keep our eye on what will truly defeat the opioid crisis.

As the public debate on health reform rolls on, a new report analyzes how these different approaches could impact insurers' bottom lines.

A House panel is going to consider several changes to Nancy Pelosi's drug prices plan, including stiff penalties for not being transparent.